Merck Patent Gmbh

Merck Patent Gesellschaft MIT Beschrankter Haftung

Hans Michael Eggenweiler

Christian Sirrenberg

Hans Peter Buchstaller

Dieter Dorsch

Michael Wolf

Guenter Hoelzemann

Compounds of the formula I are inhibitors of TBK1 and IKK&#x3b5; and can be employed, inter alia, for the treatment of cancer and inflammatory diseases.

Furo[3,2-b]- and thieno[3,2-b]pyridin derivatives

Novel quinazolinamide derivatives of the formula (I), in which R-Rand X have the meanings indicated in Claim, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.

Quinazoline derivatives

5-[4-(2-Methylphenyl)-3-hydroxy-4H-1,2,4-triazol-5-yl]-2,4-dihydroxy-N-methyl-N-butylbenzamide is an HSP90 inhibitor and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.

Triazole derivative as an HSP 90 inhibitor

Novel 1,3-dihydroisoindole derivatives of the formula (I), in which R-Rhave the meanings indicated in claim, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.

Growing community of inventors

Darmstadt, Germany

Hans Michael Eggenweiler